Meet the EAB 2004

ACT Editorial Advisory Board members are experts in their field who volunteer to review and comment on manuscripts being considered for publication. EAB members also provide valuable feedback on special programs and projects as well as keep our editorial staff current on the state of the industry. ACT would like to welcome two new members to our Editorial Advisory Board, Scott Grisanti and Uwe Gudat, as well as introduce them to our readers.

Scott Grisanti serves as Senior Vice President, Business Development and Chief Marketing Officer for eResearchTechnology (eRT), which provides technology and services to optimize the digital collection, management, analysis, and distribution of cardiac safety and clinical data throughout the new drug development process. In this capacity, Scott is responsible for managing eRT's global sales, marketing, and alliance activities. He has worked extensively with sponsors in the pharmaceutical, biotechnology, and medical device segments, along with CROs and government organizations, to help enhance and accelerate key clinical development processes and ensure effective compliance with emerging regulatory imperatives. Scott has published articles in numerous trade journals and has served as a speaker at industry events. He joined eRT from ClearCross, Inc., where he served as Area Vice President of Sales. Prior to ClearCross, he was Director of Sales for Metasys, Inc., Director of Workflow and COLD Business Development for Computron Software, and Director of UNIX Product Marketing for Information Builders, Inc. Scott graduated Rutgers University, where he was elected to Phi Beta Kappa and named a Rutgers Scholar.

Scott Grisanti, eResearchTechnology (eRT).

Uwe Gudat, MD, received his medical degree from the Philipps University in Marburg, Germany. He then moved on to the University of Dusseldorf, Germany, where he trained in internal medicine and diabetology, in the Department of Metabolism and Nutrition, a WHO collaborating center for diabetes. During this time he conducted research on the effects of exercise on metabolic control in patients with diabetes and practical aspects of health care delivery for diabetic patients. In 1995 Uwe joined the pharmaceutical industry at Eli Lilly & Company in Bad Homburg, Germany, where he was instrumental in Phase III and IV development of Insulin lispro and its fixed mixtures. In 1999 he moved to Switzerland, to take up a position as medical director of the CRO Hesperion in Basel. In 2001, he founded Aretaeus, a consultancy firm providing expertise and services for clinical development in the field of diabetes and related metabolic disorders. One year ago, Uwe joined Novartis Pharmaceuticals, where he is currently a clinical project leader. He has published research papers, reviews, and book chapters in the field of diabetes, and has been a regular contributor to the ACT European Summit conferences.

Uwe Gudat, Novartis Pharmaceuticals